دورية أكاديمية

Summary of Research: Adjuvant Nivolumab Plus Ipilimumab Versus Placebo for Localized Renal Cell Carcinoma After Nephrectomy (CheckMate 914): A Double-Blind, Randomized, Phase 3 Trial

التفاصيل البيبلوغرافية
العنوان: Summary of Research: Adjuvant Nivolumab Plus Ipilimumab Versus Placebo for Localized Renal Cell Carcinoma After Nephrectomy (CheckMate 914): A Double-Blind, Randomized, Phase 3 Trial
المؤلفون: Motzer, Robert J., Russo, Paul, Grünwald, Viktor, Tomita, Yoshihiko, Zurawski, Bogdan, Parikh, Omi, Buti, Sebastiano, Barthélémy, Philippe, Goh, Jeffrey C., Ye, Dingwei, Lingua, Alejo, Lattouf, Jean-Baptiste, Albigès, Laurence, George, Saby, Shuch, Brian, Sosman, Jeffrey, Staehler, Michael, Vázquez Estévez, Sergio, Simsek, Burcin, Spiridigliozzi, Julia, Chudnovsky, Aleksander, Bex, Axel
المساهمون: Bristol-Myers Squibb
المصدر: Targeted Oncology ; volume 18, issue 5, page 639-641 ; ISSN 1776-2596 1776-260X
بيانات النشر: Springer Science and Business Media LLC
سنة النشر: 2023
مصطلحات موضوعية: Pharmacology (medical), Cancer Research, Oncology
نوع الوثيقة: article in journal/newspaper
اللغة: English
DOI: 10.1007/s11523-023-00987-1
DOI: 10.1007/s11523-023-00987-1.pdf
DOI: 10.1007/s11523-023-00987-1/fulltext.html
الإتاحة: https://doi.org/10.1007/s11523-023-00987-1Test
حقوق: https://creativecommons.org/licenses/by-nc/4.0Test ; https://creativecommons.org/licenses/by-nc/4.0Test
رقم الانضمام: edsbas.A7A12E77
قاعدة البيانات: BASE